Genetron (GTH) Stock Forecast, Price Target & Predictions
GTH Stock Forecast
Genetron stock forecast is as follows:
Genetron Financial Forecast
Genetron Revenue Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $137.75M | $110.32M | $146.86M | $152.54M | $140.49M | $92.06M | $133.94M | $111.96M | $101.73M |
| Avg Forecast | $321.33M | $300.57M | $281.15M | $230.90M | $216.58M | $178.99M | $167.88M | $168.71M | $160.74M | $112.38M | $16.76M | $22.42M | $23.29M | $21.74M | $13.73M | $20.02M | $15.90M | $13.02M |
| High Forecast | $321.33M | $300.57M | $281.15M | $230.90M | $216.58M | $178.99M | $167.88M | $168.71M | $160.74M | $112.38M | $16.76M | $22.42M | $23.29M | $21.74M | $13.73M | $20.02M | $15.90M | $13.02M |
| Low Forecast | $321.33M | $300.57M | $281.15M | $230.90M | $216.58M | $178.99M | $167.88M | $168.71M | $160.74M | $112.38M | $16.76M | $22.42M | $23.29M | $21.74M | $13.73M | $20.02M | $15.90M | $13.02M |
| # Analysts | - | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.23% | 6.58% | 6.55% | 6.55% | 6.46% | 6.71% | 6.69% | 7.04% | 7.81% |
Genetron's average Quarter revenue forecast for Sep 22 based on 1 analysts is $160.74M, with a low forecast of $160.74M, and a high forecast of $160.74M. GTH's average Quarter revenue forecast represents a 16.69% increase compared to the company's last Quarter revenue of $137.75M (Jun 22).
Genetron EBITDA Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | $-160.83M | $-160.89M | $-162.46M | $-123.18M | $-90.41M | $-108.89M | $-71.85M | $-46.44M | $-2.83B |
| Avg Forecast | $-302.36M | $-282.82M | $-264.55M | $-217.27M | $-203.79M | $-168.42M | $-157.96M | $-158.75M | $-151.25M | $-105.74M | $-15.77M | $-21.10M | $-66.41M | $-2.87B | $-105.64M | $-18.84M | $-60.37M | $-2.61B |
| High Forecast | $-302.36M | $-282.82M | $-264.55M | $-217.27M | $-203.79M | $-168.42M | $-157.96M | $-158.75M | $-151.25M | $-105.74M | $-15.77M | $-21.10M | $-53.13M | $-2.30B | $-84.51M | $-18.84M | $-48.30M | $-2.09B |
| Low Forecast | $-302.36M | $-282.82M | $-264.55M | $-217.27M | $-203.79M | $-168.42M | $-157.96M | $-158.75M | $-151.25M | $-105.74M | $-15.77M | $-21.10M | $-79.69M | $-3.45B | $-126.76M | $-18.84M | $-72.44M | $-3.13B |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.52% | 10.20% | 7.70% | 1.85% | 0.03% | 1.03% | 3.81% | 0.77% | 1.08% |
undefined analysts predict GTH's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Genetron's previous annual EBITDA (undefined) of $NaN.
Genetron Net Income Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | - | - |
| Net Income | - | - | - | - | - | - | - | - | - | $-234.67M | $-168.47M | $-143.90M | $-128.97M | $-91.82M | $-115.04M | $-73.22M | $-48.00M | $-2.83B |
| Avg Forecast | $346.15M | $301.34M | $352.01M | $-100.00M | $-104.69M | $-124.12M | $-128.26M | $-127.59M | $-138.96M | $-157.96M | $-168.23M | $-26.50M | $-68.64M | $-2.87B | $-111.60M | $-33.87M | $-62.40M | $-2.61B |
| High Forecast | $346.15M | $301.34M | $352.01M | $-100.00M | $-104.69M | $-124.12M | $-128.26M | $-127.59M | $-138.96M | $-157.96M | $-168.23M | $-26.50M | $-54.91M | $-2.30B | $-89.28M | $-33.87M | $-49.92M | $-2.09B |
| Low Forecast | $346.15M | $301.34M | $352.01M | $-100.00M | $-104.69M | $-124.12M | $-128.26M | $-127.59M | $-138.96M | $-157.96M | $-168.23M | $-26.50M | $-82.36M | $-3.45B | $-133.92M | $-33.87M | $-74.88M | $-3.14B |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.49% | 1.00% | 5.43% | 1.88% | 0.03% | 1.03% | 2.16% | 0.77% | 1.08% |
Genetron's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. GTH's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Genetron SG&A Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | - | - |
| SG&A | - | - | - | - | - | - | - | - | - | $154.83M | $141.09M | $165.19M | $157.61M | $143.09M | $104.27M | $116.31M | $93.00M | $88.52M |
| Avg Forecast | $338.69M | $316.81M | $296.34M | $243.38M | $228.28M | $188.66M | $176.94M | $177.83M | $169.43M | $118.45M | $17.66M | $23.63M | $24.55M | $22.91M | $14.47M | $21.10M | $16.76M | $13.73M |
| High Forecast | $338.69M | $316.81M | $296.34M | $243.38M | $228.28M | $188.66M | $176.94M | $177.83M | $169.43M | $118.45M | $17.66M | $23.63M | $24.55M | $22.91M | $14.47M | $21.10M | $16.76M | $13.73M |
| Low Forecast | $338.69M | $316.81M | $296.34M | $243.38M | $228.28M | $188.66M | $176.94M | $177.83M | $169.43M | $118.45M | $17.66M | $23.63M | $24.55M | $22.91M | $14.47M | $21.10M | $16.76M | $13.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | 1.31% | 7.99% | 6.99% | 6.42% | 6.25% | 7.21% | 5.51% | 5.55% | 6.45% |
Genetron's average Quarter SG&A projection for Sep 22 is $169.43M, based on 1 Wall Street analysts, with a range of $169.43M to $169.43M. The forecast indicates a 9.43% rise compared to GTH last annual SG&A of $154.83M (Jun 22).
Genetron EPS Forecast
| Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | - | - | - | - | - | 1 | - | - | - | - | - | - | - | - | - |
| EPS | - | - | - | - | - | - | - | - | - | $-2.53 | $-1.82 | $-1.55 | $-1.40 | $-1.00 | $-1.25 | $-0.80 | $-0.55 | $-85.20 |
| Avg Forecast | $11.17 | $9.73 | $11.36 | $-3.23 | $-3.38 | $-4.01 | $-4.14 | $-4.12 | $-4.49 | $-5.10 | $-5.43 | $-0.86 | $-0.75 | $-0.58 | $-0.35 | $-1.09 | $-1.48 | $-1.85 |
| High Forecast | $11.17 | $9.73 | $11.36 | $-3.23 | $-3.38 | $-4.01 | $-4.14 | $-4.12 | $-4.49 | $-5.10 | $-5.43 | $-0.86 | $-0.75 | $-0.58 | $-0.35 | $-1.09 | $-1.48 | $-1.85 |
| Low Forecast | $11.17 | $9.73 | $11.36 | $-3.23 | $-3.38 | $-4.01 | $-4.14 | $-4.12 | $-4.49 | $-5.10 | $-5.43 | $-0.86 | $-0.75 | $-0.58 | $-0.35 | $-1.09 | $-1.48 | $-1.85 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.50% | 0.34% | 1.81% | 1.86% | 1.74% | 3.55% | 0.73% | 0.37% | 45.94% |
According to undefined Wall Street analysts, Genetron's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to GTH previous annual EPS of $NaN (undefined).
Genetron Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| ACRS | Aclaris Therapeutics | $1.18 | $25.00 | 2018.64% | Buy |
| DRIO | DarioHealth | $0.95 | $10.75 | 1031.58% | Buy |
| NOTV | Inotiv | $1.56 | $9.00 | 476.92% | Hold |
| MDXH | MDxHealth SA | $2.62 | $15.00 | 472.52% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| XGN | Exagen | $2.96 | $6.00 | 102.70% | Buy |
| BDSX | Biodesix | $1.77 | $3.00 | 69.49% | Buy |
| CSTL | Castle Biosciences | $31.18 | $38.00 | 21.87% | Buy |
| SHC | Sotera Health Company | $16.80 | $16.93 | 0.77% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
GTH Forecast FAQ
What are Genetron's analysts' financial forecasts?
GTH's analysts financial forecasts for the fiscal year (Dec 2023) are as follows: average revenue is $794.35M (high $794.35M, low $794.35M), average EBITDA is $-747M (high $-747M, low $-747M), average net income is $-457M (high $-457M, low $-457M), average SG&A $837.26M (high $837.26M, low $837.26M), and average EPS is $-14.753 (high $-14.753, low $-14.753).
Did the GTH's actual financial results beat the analysts' financial forecasts?
Based on Genetron's last annual report (Dec 2022), the company's revenue was $650.71M, beating the average analysts forecast of $458.59M by 41.89%. Apple's EBITDA was $-546M, beating the average prediction of $-432M by 26.59%. The company's net income was $-884M, beating the average estimation of $-593M by 49.12%. Apple's SG&A was $631.47M, beating the average forecast of $483.36M by 30.64%. Lastly, the company's EPS was $0, missing the average prediction of $-19.132 by -100.00%. In terms of the last quarterly report (Jun 2022), Genetron's revenue was $137.75M, beating the average analysts' forecast of $112.38M by 22.58%. The company's EBITDA was $-161M, beating the average prediction of $-106M by 52.09%. Genetron's net income was $-235M, beating the average estimation of $-158M by 48.56%. The company's SG&A was $154.83M, beating the average forecast of $118.45M by 30.72%. Lastly, the company's EPS was $-2.53, missing the average prediction of $-5.099 by -50.38%